慢性乙型肝炎病毒感染
Wai-Kay Seto1, Ying-Ru Lo2, Jean-Michel Pawlotsky3
1Department of Medicine, The University of Hong Kong Queen Mary Hospital, Hong Kong Special Administrative Region, China; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong Special Administrative Region, China.
乙型肝炎病毒感染构成全球健康风险,但疫苗接种和有效治疗可显著减少慢性传播和疾病进展. 优化管理和开发新疗法是2030年消除这种疾病的关键.
科学领域:
- 肝病学
- 病毒学
- 公共卫生
背景情况:
- 慢性乙型肝炎病毒 (HBV) 感染是全球的主要健康问题,导致严重的肝脏相关疾病和死亡.
- 传染发生在出生时或通过人与人接触,这凸显了预防措施的重要性.
- 在长期感染的个体中,HBV DNA水平升高是疾病进展的主要危险因素.
研究的目的:
- 审查B型肝炎病毒感染管理的现状.
- 突出诊断,治疗和预防策略的进步.
- 评估世界卫生组织到2030年消除乙型肝炎病毒的可行性.
主要方法:
- 对B型肝炎病毒流行病学,发病和治疗的现有文献的审查.
- 分析当前的诊断和监测工具,包括非侵入性纤维化评估.
- 核相对应疗法的疗效和安全性评估.
- 对正在开发中的新疗法进行评估.
主要成果:
- 疫苗在预防HBV感染和慢性携带方面非常有效.
- 核类药物治疗提供安全有效的病毒抑制,减少肝脏并发症.
- 非侵入性纤维化评估是传统方法的新兴重要工具.
- 许多有前途的新疗法正在开发中,
结论:
- 有效的治疗策略,包括疫苗接种,有效的抗病毒疗法和改善的护理联系,对于控制慢性HBV感染至关重要.
- 通过持续的进步和全球努力,到2030年消除乙型肝炎病毒作为全球健康威胁的目标是可以实现的.
相关概念视频
What are Viruses?
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Hepatic Drug Excretion: Influencing Factors


